Canagliflozin (Hemihydrate): Precision SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a selective small molecule inhibitor of sodium-glucose co-transporter 2 (SGLT2), widely used in metabolic disorder and diabetes mellitus research (APExBIO C6434). The compound exhibits high purity (≥98%) and rigorous characterization via HPLC and NMR, ensuring reproducibility. It is chemically stable at -20°C and demonstrates excellent solubility in organic solvents, enabling flexible experimental design. Peer-reviewed evidence confirms that Canagliflozin (hemihydrate) does not inhibit mTOR or TOR signaling pathways (GeroScience 2025). This article clarifies its mechanistic scope and experimental benchmarks for translational researchers.

Biological Rationale

Canagliflozin (hemihydrate), also known as JNJ 28431754 hemihydrate, is a small molecule SGLT2 inhibitor chemically defined as C₂₄H₂₆FO_5.5S with a molecular weight of 453.52 g/mol (APExBIO C6434). SGLT2 is primarily expressed in the renal proximal tubule and mediates reabsorption of filtered glucose from the glomerular filtrate. Inhibition of SGLT2 leads to increased urinary glucose excretion, thereby reducing blood glucose levels—an essential mechanism for studies in diabetes mellitus and glucose homeostasis (Internal Reference 1). Unlike mTOR inhibitors, Canagliflozin's effects are restricted to glucose reabsorption pathways and do not overlap with nutrient-sensing or protein synthesis regulation mechanisms. This pathway specificity is crucial for delineating experimental outcomes in metabolic research, especially when distinguishing SGLT2 inhibition from mTOR-related processes (Internal Reference 3).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) binds selectively to SGLT2, inhibiting sodium-dependent glucose transport in the kidney. This action decreases renal glucose reabsorption and increases urinary glucose excretion. The compound is not a substrate or inhibitor of mTOR, TORC1, or TORC2 complexes (GeroScience 2025). Functional studies reveal no effect on mTOR pathway activity or related growth inhibition phenotypes in yeast or mammalian models at concentrations up to 100 μM. The molecular structure features a fluorophenyl-thiophene core, facilitating high affinity and specificity for SGLT2. The hemihydrate form ensures improved stability and handling in laboratory settings. The compound is insoluble in water but dissolves efficiently in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL), supporting diverse assay formats.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) does not inhibit TOR/mTOR signaling in drug-sensitized yeast models at concentrations up to 100 μM (Breen et al., GeroScience 2025).
• HPLC and NMR analyses confirm product purity ≥98%, supporting reproducible results in glucose metabolism research (APExBIO C6434).
• Solubility benchmarks: ≥40.2 mg/mL in ethanol, ≥83.4 mg/mL in DMSO; storage at -20°C recommended for stability (APExBIO C6434).
• Renal glucose reabsorption inhibition is robust and specific, with no off-target effects on mTOR or related metabolic pathways (Internal Reference 2).
• Ideal for experimental workflows requiring rapid solution preparation; long-term storage of solutions is discouraged to maintain efficacy (APExBIO C6434).

This article extends analyses from Canagliflozin (Hemihydrate): Precise SGLT2 Inhibitor by providing new evidence on mTOR pathway selectivity, and updates Canagliflozin Hemihydrate: Unraveling Renal Glucose Reabsorption Inhibition with recent solubility and workflow benchmarks.

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is utilized in cellular, animal, and ex vivo systems to model SGLT2-mediated glucose homeostasis and study metabolic disorders, especially diabetes mellitus. The compound enables pathway-specific intervention, which is essential for dissecting renal glucose reabsorption mechanisms. Its lack of effect on mTOR allows for precise attribution of observed phenotypes to SGLT2 inhibition. Researchers can use Canagliflozin (hemihydrate) to differentiate between SGLT2-dependent and mTOR-dependent metabolic processes (Internal Reference 4).

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) is not an mTOR, TORC1, or TORC2 inhibitor; it has no effect on these pathways at standard research concentrations (GeroScience 2025).
• It should not be used for diagnostic or therapeutic purposes; it is strictly intended for research use only (APExBIO C6434).
• Long-term storage of prepared solutions is not recommended due to potential loss of potency (APExBIO C6434).
• The compound is not effective in studying protein synthesis or autophagy pathways regulated by mTOR.
• Canagliflozin (hemihydrate) is insoluble in water—incorrect solvent selection can compromise assay performance.

Workflow Integration & Parameters

Canagliflozin (hemihydrate) is supplied by APExBIO as a high-purity powder, validated by HPLC and NMR. The recommended storage condition is -20°C, with shipping on blue ice for small molecule stability. Reconstitution should be performed in DMSO or ethanol to attain working concentrations (≥83.4 mg/mL in DMSO, ≥40.2 mg/mL in ethanol). Immediate use of solutions is advised to preserve analytical integrity. The compound supports a wide range of metabolic and diabetes research models, including but not limited to in vitro SGLT2 activity assays, glucose uptake studies, and in vivo glucose tolerance tests. Researchers should verify solvent compatibility with their experimental system and avoid prolonged exposure to aqueous buffers. For comparative purposes, Canagliflozin (hemihydrate) can be used alongside other SGLT2 inhibitors to benchmark selectivity and potency.

Conclusion & Outlook

Canagliflozin (hemihydrate) is a rigorously characterized, pathway-specific SGLT2 inhibitor that enables advanced research in glucose metabolism and diabetes mellitus. Its selectivity profile is validated by negative results in mTOR inhibition assays and robust positive controls in SGLT2-dependent models. Researchers benefit from the compound's high stability, purity, and solubility parameters, supporting reproducible results across workflows. For more details or to obtain the C6434 kit, visit the APExBIO Canagliflozin (hemihydrate) product page. This article updates and clarifies recent findings, distinguishing SGLT2 inhibition from mTOR pathway interventions and guiding best practices in metabolic disorder research.